These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

729 related items for PubMed ID: 2073667

  • 1. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis.
    Alberts AW.
    Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667
    [Abstract] [Full Text] [Related]

  • 2. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H, Fager G.
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [Abstract] [Full Text] [Related]

  • 3. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
    Mosley ST, Kalinowski SS, Schafer BL, Tanaka RD.
    J Lipid Res; 1989 Sep; 30(9):1411-20. PubMed ID: 2513368
    [Abstract] [Full Text] [Related]

  • 4. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin.
    Chao Y, Chen JS, Hunt VM, Kuron GW, Karkas JD, Liou R, Alberts AW.
    Eur J Clin Pharmacol; 1991 Sep; 40 Suppl 1():S11-4. PubMed ID: 2044637
    [Abstract] [Full Text] [Related]

  • 5. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
    Cohen LH, van Vliet A, Roodenburg L, Jansen LM, Griffioen M.
    Biochem Pharmacol; 1993 Jun 09; 45(11):2203-8. PubMed ID: 8517861
    [Abstract] [Full Text] [Related]

  • 6. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
    Masters BA, Palmoski MJ, Flint OP, Gregg RE, Wang-Iverson D, Durham SK.
    Toxicol Appl Pharmacol; 1995 Mar 09; 131(1):163-74. PubMed ID: 7878672
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
    Aoki T, Nishimura H, Nakagawa S, Kojima J, Suzuki H, Tamaki T, Wada Y, Yokoo N, Sato F, Kimata H, Kitahara M, Toyoda K, Sakashita M, Saito Y.
    Arzneimittelforschung; 1997 Aug 09; 47(8):904-9. PubMed ID: 9296275
    [Abstract] [Full Text] [Related]

  • 8. Regulation of early cholesterol biosynthesis in rat liver: effects of sterols, bile acids, lovastatin, and BM 15.766 on 3-hydroxy-3-methylglutaryl coenzyme A synthase and acetoacetyl coenzyme A thiolase activities.
    Honda A, Salen G, Nguyen LB, Xu G, Tint GS, Batta AK, Shefer S.
    Hepatology; 1998 Jan 09; 27(1):154-9. PubMed ID: 9425931
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of long-term administration of HMG-CoA reductase inhibitors on cholesterol synthesis in lens.
    Kalinowski SS, Tanaka RD, Mosley ST.
    Exp Eye Res; 1991 Aug 09; 53(2):179-86. PubMed ID: 1915674
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug.
    Vickers S, Duncan CA, Chen IW, Rosegay A, Duggan DE.
    Drug Metab Dispos; 1990 Aug 09; 18(2):138-45. PubMed ID: 1971563
    [Abstract] [Full Text] [Related]

  • 14. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
    Slater EE, MacDonald JS.
    Drugs; 1988 Aug 09; 36 Suppl 3():72-82. PubMed ID: 3076125
    [Abstract] [Full Text] [Related]

  • 15. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors.
    Sirtori CR.
    Pharmacol Ther; 1993 Dec 09; 60(3):431-59. PubMed ID: 8073070
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of sustained/controlled-release dosage forms of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors in dogs and humans.
    Cheng H, Sutton SC, Pipkin JD, Zentner GM, Rogers JD, Schwartz JI, Mitchel YB, Grasing K, Schwartz MS, Amin RD.
    Pharm Res; 1993 Nov 09; 10(11):1683-7. PubMed ID: 8290485
    [Abstract] [Full Text] [Related]

  • 17. Bile acid derived HMG-CoA reductase inhibitors.
    Kramer W, Wess G, Enhsen A, Bock K, Falk E, Hoffmann A, Neckermann G, Gantz D, Schulz S, Nickau L.
    Biochim Biophys Acta; 1994 Nov 29; 1227(3):137-54. PubMed ID: 7986821
    [Abstract] [Full Text] [Related]

  • 18. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
    Qin W, Infante J, Wang SR, Infante R.
    Biochim Biophys Acta; 1992 Jul 09; 1127(1):57-66. PubMed ID: 1627634
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.